The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | The evolving role of stem cell transplantation in MPNs
In this video, Uday Popat, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly comments on the increasing role of stem cell transplantation in myeloproliferative neoplasms (MPNs) with the advent of novel therapies. Prof. Popat notes that, while novel therapies are not curative, they lead to improved disease control and reduced spleen size, resulting in an increase in the number of patients being selected to undergo transplant. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So with novel therapies, none of those therapies are curative as of today. So as a matter of fact, novel therapies lead to further reduction in spleen size and improve disease control. So we are actually doing more and more transplants with the availability of novel therapies. You know, when I started this 20 years ago, we would do three or four transplants a year and now this year we’ll do about 30 to 35 transplants a year with this...
So with novel therapies, none of those therapies are curative as of today. So as a matter of fact, novel therapies lead to further reduction in spleen size and improve disease control. So we are actually doing more and more transplants with the availability of novel therapies. You know, when I started this 20 years ago, we would do three or four transplants a year and now this year we’ll do about 30 to 35 transplants a year with this. So actually the numbers are going up.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: TScan Therapeutics, Medscape, Illuminate Health, Daiichi Sankyo, Binaytara Foundation, South Piedmont Area Health Education Center (AHEC), MD Education Limited; Scientific Advisory Board: TScan Therapeutics, Medscape, Illuminate Health, Daiichi Sankyo, Binaytara Foundation, South Piedmont Area Health Education Center (AHEC), MD Education Limited; Speaker Fees: TScan Therapeutics, Medscape, Illuminate Health, Daiichi Sankyo, Binaytara Foundation, South Piedmont Area Health Education Center (AHEC), MD Education Limited; Professional Society Activities: American Society for Transplantation and Cellular Therapy (ASTCT).
